Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Phillip Jeffrey

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Drug News & Perspectives|July 20, 2007
Addressing the innovation gapPhillip Jeffrey, Peter Warne, Robert Williams
British Journal of Clinical Pharmacology|April 14, 2012
Human microdose evaluation of the novel EP1 receptor antagonist GSK269984AThor Ostenfeld, Claire Beaumont, Jonathan Bullman, et al.
Bioanalysis|January 26, 2021
Development of a LC-MS/MS method for the quantification of toxic payload DM1 cleaved from BT1718 in a Phase I studyCatherine Gowland, Philip Berry, Julie Errington, et al.
Bioorganic & Medicinal Chemistry Letters|October 24, 2002
SB-656104-A: a novel 5-HT(7) receptor antagonist with improved in vivo propertiesIan T Forbes, Sara Douglas, Andrew D Gribble, et al.
Bioorganic & Medicinal Chemistry Letters|July 15, 2006
SAR of biphenyl carboxamide ligands of the human melanin-concentrating hormone receptor 1 (MCH R1): discovery of antagonist SB-568849David R Witty, John H Bateson, Guillaume J Hervieu, et al.
Bioorganic & Medicinal Chemistry Letters|July 15, 2006
Discovery of potent and stable conformationally constrained analogues of the MCH R1 antagonist SB-568849David R Witty, John Bateson, Guillaume J Hervieu, et al.
British Journal of Pharmacology|June 19, 2003
SB-656104-A, a novel selective 5-HT7 receptor antagonist, modulates REM sleep in ratsDavid R Thomas, Sergio Melotto, Mario Massagrande, et al.
Journal of Medicinal Chemistry|September 11, 2013
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomainsOlivier Mirguet, Romain Gosmini, Jérôme Toum, et al.
Journal of Medicinal Chemistry|October 31, 2003
Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): a potent and selective dopamine D3 receptor antagonistGregor J Macdonald, Clive L Branch, Michael S Hadley, et al.
Nature|October 4, 2011
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemiaMark A Dawson, Rab K Prinjha, Antje Dittmann, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Drug News & Perspectives|July 20, 2007
Addressing the innovation gapPhillip Jeffrey, Peter Warne, Robert Williams
British Journal of Clinical Pharmacology|April 14, 2012
Human microdose evaluation of the novel EP1 receptor antagonist GSK269984AThor Ostenfeld, Claire Beaumont, Jonathan Bullman, et al.
Bioanalysis|January 26, 2021
Development of a LC-MS/MS method for the quantification of toxic payload DM1 cleaved from BT1718 in a Phase I studyCatherine Gowland, Philip Berry, Julie Errington, et al.
Bioorganic & Medicinal Chemistry Letters|October 24, 2002
SB-656104-A: a novel 5-HT(7) receptor antagonist with improved in vivo propertiesIan T Forbes, Sara Douglas, Andrew D Gribble, et al.
Bioorganic & Medicinal Chemistry Letters|July 15, 2006
SAR of biphenyl carboxamide ligands of the human melanin-concentrating hormone receptor 1 (MCH R1): discovery of antagonist SB-568849David R Witty, John H Bateson, Guillaume J Hervieu, et al.
Bioorganic & Medicinal Chemistry Letters|July 15, 2006
Discovery of potent and stable conformationally constrained analogues of the MCH R1 antagonist SB-568849David R Witty, John Bateson, Guillaume J Hervieu, et al.
British Journal of Pharmacology|June 19, 2003
SB-656104-A, a novel selective 5-HT7 receptor antagonist, modulates REM sleep in ratsDavid R Thomas, Sergio Melotto, Mario Massagrande, et al.
Journal of Medicinal Chemistry|September 11, 2013
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomainsOlivier Mirguet, Romain Gosmini, Jérôme Toum, et al.
Journal of Medicinal Chemistry|October 31, 2003
Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): a potent and selective dopamine D3 receptor antagonistGregor J Macdonald, Clive L Branch, Michael S Hadley, et al.
Nature|October 4, 2011
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemiaMark A Dawson, Rab K Prinjha, Antje Dittmann, et al.
Pageof 2